Member Info for MBUski

Someone's been working very hard, for a very long time, to keep this share price down, look at those sells!

Fingers crossed for next week... background off platform accumulation peut etre?

Yes but that was before the October RNS which stated.... Fixed remuneration reduction: From 1 November 2025 there will be a 50 per cent reduction in the salaries of the two Board directors, Jane McCracken and Iain Ross, and Tern's executive managers Al Sisto and Bruce Leith. This is expected to provide a saving of approximately £153,000 on an annualised basis.

I would also hope that the liaison/coordination overheads associated with SVV would also decline and given Tern is not actively looking at new investments, I would also hope that the Exec team could be removed or at least put onto zero hours contracts.

It was always a questionable investment that defied logic! I am pleased to be out of it. Now its just a waiting game for portfolio exits, so management costs should be minimal.

Little faith... going into my 13th year... OMG!

Been here since 2013, let's hope it's not another Nanoco, I seem to remember that samsung were an early ilika partner and we know what went down there!

C11 Merry Xmas to you and yours🎅🕯️🎄

Burble, received pretty much the same response from Phil last night with a link to the presentation. Will take a look over the festive period. Thanks again.

Chester, thanks, that's what you get for going on month long tour of Costa Rica. The top team is certainly qualified to bring it home, so I hope you are right. For me, Modi and/or GT news are the only things that will change the current SP. There's not much more they can say on SCB1+. The recent RNS was a bit of a damp squib, and we're lucky it didn't have a negative effect, given expectations. There's always a chance it was aimed at a potential partner and for completeness they felt the need to update everyone, we can but hope. Something's got to catalyse this moribund price so fingers crossed for the new year!

Happy Christmas one and all and thanks for all your efforts in 2025. I don't contribute much, but I value your contributions.

Burble, thanks I missed that -I had Q4 and December in my head and was rather hoping for an update this morning. I do wonder what the hold up is though, and equaly, an update on what they are doing with GT, which is the one I was really hoping for.

I've got a lot of faith in Scancell, it is by far my biggest holding, I'd like to think they're just waiting to issue a mega RNS, but recent sells and silence makes me wonder if like other companies they'll try and sneak bad news out when they hope less people are watching. I truly hope not.

We were promised the overdue Modi update in Q4. I've messaged the company but not had a response. Do you think we will get one?

Chester18 I think you're right, trial results have always been well signalled in advance so have never really had the impact they should warrant. My expectation remains a GT announcement, hopefully a full sale of the Glymab platform at top dollar, and a special dividend to shareholders early next year. One can but hope for a pre-Christmas miracle! Seasons Greetings one and all.

GG sorry for the delay in responding, been in here for over 4 years and managed to exit my original investment on the spike so sitting reasonably happy at the moment. I have to admit, as a former CEO myself, that I find Tim very frustrating, but I have a strong belief in the French lab and the science so have continued to average down on every drop. The spike though was a big relief! Fingers crossed...

GG let's hope so - the hope'ium part of me is thinking that the RNS may have been issued as part of a negotiating play and a deal might still come along... but I've been here a long time so....

Large late trades from yesterday lo look like sells, can anyone confirm?

It's a late stage asset with a proven safety record being relaunched with a much expanded use case, clear targeting criteria, supported by eligibility testing, all after FDA advice/direction to increase dosing limits... surely it's got to be £2-3+

Violindog there's a reason it's called Scancell Holdings ;-)

It's another Diggle wiggle;-)

All nicely on track....

"Development of the first Genmab partnered SC129 remains on track with further milestones payments anticipated in the near-term."

"Establishing GlyMab Therapeutics Limited to hold our antibody assets brings corporate clarity, with the team determined to realise the GlyMab® platform's real value."